Skip to main content
OpenTrials
Completed

NCT Number: NCT00901745

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the diameter of blood vessels.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc

Edinburgh, EH16 4SA, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • > 18 years old
  • Healthy volunteers

Exclusion criteria

  • Lack of informed consent
  • Age < 18 years,
  • Current involvement in other research studies,
  • Systolic blood pressure >190 mmHg or <100 mmHg
  • Malignant arrhythmias
  • Renal or hepatic failure
  • Haemodynamically significant aortic stenosis
  • Severe or significant co morbidity
  • Women of childbearing potential.
  • Any regular medication
  • Previous history of any cardiovascular disease

Treatment and study plan

Angiotensin II

Drug

Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.

Noradrenaline infusion

Drug

Infusion of up to 480 picomol/ml of noradrenaline will be infused.

Primary outcomes

  1. Change in angiotensin II mediated vasoconstriction

    Time frame: 12 months

Secondary outcomes

  1. Changes in relevant neurohumoral hormones in response to apelin infusion

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

University of Edinburgh

Other

Registry information

Official study title

Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
May 14, 2009
Registry last updated
Aug 10, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.